CHAM
KYMR icon

Clear Harbor Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Clear Harbor Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,194
Closed -$489K – 439
2025
Q2 		$489K Buy
11,194
+838
+8% +$28.9K 0.04% 275
2025
Q1 		$283K Buy
10,356
+356
+4% +$13K 0.02% 329
2024
Q4 		$402K Hold
10,000
– – 0.03% 271
2024
Q3 		$473K Hold
10,000
– – 0.04% 240
2024
Q2 		$299K Hold
10,000
– – 0.03% 291
2024
Q1 		$402K Hold
10,000
– – 0.04% 250
2023
Q4 		$255K Buy
+10,000
New +$179K 0.02% 299

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Clear Harbor Asset Management's KYMR Position: Q3 2025 in Review

Clear Harbor Asset Management sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 11,194 shares — an estimated $489K sold.

Clear Harbor Asset Management first reported a position in KYMR in Q4 2023 and held it in 7 quarters. The position peaked at $489K in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Clear Harbor Asset Management reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Clear Harbor Asset Management sold 11,194 Kymera Therapeutics shares in Q3 2025, an estimated $489K.
  • Clear Harbor Asset Management first reported a position in Kymera Therapeutics in Q4 2023 and held it in 7 quarters.
  • Clear Harbor Asset Management's Kymera Therapeutics position peaked at $489K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Clear Harbor Asset Management's 13F filing for Q3 2025, filed 23 Oct 2025.